Speaker illustration

Doctor Angelos Liontos

University hospital of Ioannina, Ioannina (Greece)

Member of:

European Society of Cardiology

Introduction: Internal Medicine Specialist. Experienced Medical Doctor with a demonstrated history of working in the Medical Practice industry. Skilled in Emergency Medicine, Healthcare, Clinical Research, and Medical Education. PhD in Medicine in Arterial Hypertension and Prediabetes, Medical School, University of Ioannina, Greece. University Hospital of Ioannina. MSc in Thrombosis and Antithrombotic Treatment, University of Thessaly, Larissa Medical School, Greece. Disciplines: Internal Medicine (General Medicine), Clinical Trials, Diabetology, Hypertension Skills and expertise: Lipid Metabolism, Triglycerides, Lipoproteins, Insulin Resistance, Metabolism, Metabolic Diseases, Glucose Metabolism, Atherosclerosis, HypertensionMetabolic SyndromeRisk PredictionDisease PreventionCardiovascular EpidemiologyStatinsLow Density LipoproteinsCOVID-19Thrombosisantithrombotic treatmentStroke ImagingBrain InfarctionStrokeStroke MedicineIschemic StrokeStroke Prevention

Gamma-glutamyl Transferase and insulin resistance. Various effects of RAS-blockade plus CCB combination: results from a randomized 12-week open-label comparative study

Event: ESC Preventive Cardiology 2023

Topic: Pharmacotherapy

Session: Moderated ePoster 3

Thumbnail

Target attainment of Blood Pressure goals with RAS-blockers plus CCB, according to ESC 2018 and 2021 guidelines. Results from a randomized 12-week open-label comparative study

Event: ESC Preventive Cardiology 2023

Topic: Epidemiology, Prognosis, Outcome

Session: Moderated ePoster 3

Thumbnail

Indices of renal function alternation with RAS-blockers plus CCB combinations: a randomized 12-week open-label comparative study

Event: ESC Preventive Cardiology 2023

Topic: Pharmacotherapy

Session: Moderated ePoster 3

Thumbnail

Comparative effect of 3 different fix-combination antihypertensive treatments in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: Hypertension - Pharmacotherapy

Thumbnail

Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with telmisartan/amlodipine in prediabetic hypertensive patients

Event: ESC Preventive Cardiology 2022

Topic: Pharmacotherapy

Session: ePosters

Thumbnail

Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with manidipine/delapril in prediabetic hypertensive patients

Event: ESC Preventive Cardiology 2022

Topic: Pharmacotherapy

Session: ePosters

Thumbnail

Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with telmisartan/amlodipine in prediabetic patients

Event: ESC Preventive Cardiology 2022

Topic: Pharmacotherapy

Session: ePosters

Thumbnail

Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with valsartan/amlodipine in prediabetic patients

Event: ESC Preventive Cardiology 2022

Topic: Pharmacotherapy

Session: ePosters

Thumbnail

Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with delapril/manidipine in prediabetic hypertensive patients

Event: ESC Preventive Cardiology 2022

Topic: Pharmacotherapy

Session: ePosters

Thumbnail

Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with valsartan/amlodipine in prediabetic hypertensive patients

Event: ESC Preventive Cardiology 2022

Topic: Pharmacotherapy

Session: ePosters

Thumbnail